In the present study, the clinical outcome of NSCLC patients treated with gefitinib in the context of an expanded access program (EAP) was analysed according to the presence of classical or ‘other’ variants of EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.